Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Ethnicity in the Treatment of UC
| Condition | Inflammatory Bowel Diseases |
|---|---|
| Phase | N/A |
| Sponsor | First Affiliated Hospital of Kunming Medical University |
| Status | Completed |
| Enrollment | 102 participants |
| Interventions | Fecal microbiota transplantation |
| Start date | Oct 14, 2024 |
| Completion date | Oct 20, 2025 |
| Results posted | Jun 30, 2026 |
Summary
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), affects over 2 million people worldwide . Although biological therapies have significantly improved the treatment outcomes for UC, nearly two-thirds of patients experience diminishing drug responses over time, making it crucial to explore novel therapeutic approaches targeting the underlying pathophysiology of UC. UC is associated with alterations in gut microbiota, reduced microbial diversity, and changes in the relative abundance of dominant bacterial populations. Specifically, UC patients exhibit a marked decrease in gut microbiota diversity at the species level, with a reduction in Firmicutes (e.g., Clostridium butyricum) and an increase in Actinobacteria, Proteobacteria (e.g., Escherichia coli), Enterobacteriaceae, Streptococcus, and Bacteroides . Given the association between gut microbiota alterations and IBD activity, several studies have proposed microbiota-based therapies, particularly fecal microbiota transplantation (FMT), as a treatment for UC.
a Composite of Steroid-free Clinical Remission Together With Endoscopic Remission or Response
| the Bai Nationality-UC | 24 Participants |
|---|---|
| the Han Nationality-UC | 16 Participants |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Coliti — Janssen Research & Development, LLC
- GI Permeability Change in Response to Aquamin® — James Varani
- A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Seve — Hoffmann-La Roche
- A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerativ — Janssen Research & Development, LLC
- A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Mode — Janssen Research & Development, LLC
- ENhanced Recovery in CHildren Undergoing Surgery — Northwestern University